Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
Sherene Loi(The University of Melbourne), Christos Sotiriou(Université Libre de Bruxelles), Maria Grazia Daidone(Fondazione IRCCS Istituto Nazionale dei Tumori), Christine Desmedt(Breast Cancer Research Foundation), K W Ryder(Guy's Hospital), Pratyaksha Wirapati(SIB Swiss Institute of Bioinformatics), Cheryl Gillet(Guy's Hospital), Gianluca Bontempi(Université Libre de Bruxelles), Mauro Delorenzi(SIB Swiss Institute of Bioinformatics), Maurice P.H.M. Jansen(Erasmus MC Cancer Institute), Martine Piccart(Université Libre de Bruxelles), James F. Reid(IFOM), John A. Foekens(National Cancer Centre Japan), Andrew M Tutt(Guy's Hospital), Els M.J.J. Berns(Erasmus MC Cancer Institute), Marco A. Pierotti(Società Italiana di Nefrologia), Françoise Lallemand(Institut Jules Bordet), Benjamin Haibe‐Kains(University of Toronto)
Cited by 406
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k